TNF and Respiratory tract infection: Subgroup analyses were performed for the major immunotherapies; overall symptoms of respiratory tract infections were significantly less frequent in patients treated with ustekinumab (31.8%, p=0.031), infliximab (31.6%, p=0.005), and all TNF inhibitors (infliximab, adalimumab, and golimumab; 34.5%, p=0.033) as compared to patients without immunotherapies (42.6%).